Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study
We determined first- and second-line regimens, including hematopoietic stem cell transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged >= 20 yr (n = 1,888), registered at the Belgian Cancer Registry (2013-2015). Treatments were inferred from reimbursed drugs, and procedures registered in national health insurance databases. This real-world population-based study allows to assess patients usually excluded from clinical trials such as those with comorbidities, other malignancies (12%), and advanced age (28% are >= 80 yr old). Our data show that the majority of older... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journalarticle |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Medicine and Health Sciences / Cancer Research / Oncology / DLBCL / diffuse large B cell lymphoma / population-based cancer registry / health insurance database / first- and second-line therapy / R-CHOP / hematopoietic stem cell transplantation / comorbidities / real-world studies (RWS) / ELDERLY-PATIENTS / TREATMENT-INTENSITY / TREATMENT PATTERNS / CHOP CHEMOTHERAPY / PROGNOSTIC INDEX / OLDER PATIENTS / RITUXIMAB / SURVIVAL / OUTCOMES / STAGE |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27304675 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://biblio.ugent.be/publication/8743070 |